Related Experiment Videos
Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease
The Cochrane Database of Systematic Reviews
|June 14, 2003
Summary
Oral mucolytics significantly reduce exacerbations and disability days for chronic bronchitis and COPD patients. These treatments offer a beneficial option for managing these respiratory conditions.
Area of Science:
- Respiratory Medicine
- Pharmacology
Background:
- Chronic bronchitis and COPD patients experience recurrent exacerbations.
- Exacerbations involve increased sputum volume/purulence.
- Effective therapies reducing exacerbations are needed.
Purpose of the Study:
- To assess the effects of oral mucolytics in adults with stable chronic bronchitis or COPD.
Main Methods:
- Searched Cochrane Airways Group trials register and article reference lists.
- Included randomized trials comparing oral mucolytics with placebo for ≥2 months.
- Excluded studies on asthma and cystic fibrosis.
Main Results:
- Oral mucolytics significantly reduced exacerbation frequency by 29% compared to placebo.
- A significant reduction in disability days was observed.
- More patients remained exacerbation-free with mucolytics.
Conclusions:
- Oral mucolytics are associated with a reduction in acute exacerbations in COPD and chronic bronchitis.
- Treatment also led to a greater reduction in total disability days.